Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06862050 · ClinicalTrials.gov registry record · NA

BREATHE Free: a Pilot Feasibility Trial

A NA study of E-Cig Use and Smoking Cessation; Tobacco Dependence, sponsored by Augusta University.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT06862050: Recruiting NA study of E-Cig Use and Smoking Cessation; Tobacco Dependence, sponsored by Augusta University.

NCT06862050 is a NA study of E-Cig Use and Smoking Cessation; Tobacco Dependence that is actively recruiting participants, run by Augusta University. The registered enrollment target is 90 participants, below the 142-participant average among 9 other E-Cig Use trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06862050, a NA study of E-Cig Use and Smoking Cessation; Tobacco Dependence, is actively recruiting participants, sponsored by Augusta University.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The overall purpose of this pilot study is to assess the feasibility and acceptability of an in-person faith-based intervention to help people stop tobacco use. The study will address use of different types of tobacco products, such as smoking combustible cigarettes, cigarillos and little filtered cigars, and using/vaping electronic nicotine delivery systems (vape pens, e-cigs, and JUUL). The intervention consists of 12 weekly meetings in which participants will go through BREATHE Free, a study guide curriculum designed to teach character strengths and promote resilience. This pilot research will provide information and practical lessons on how to improve Breathe Free implementation, increase engagement of the local people, and maximize their benefit. The main questions it aims to answer are: * Do participants find BREATHE Free curriculum acceptable, engaging and helpful to stop tobacco use? * Do participants who complete BREATHE Free curriculum smoke fewer cigarettes per day? Researchers will assign participants to either BREATHE Free curriculum or usual care. Participants will: * Be taught BREATHE Free curriculum or be given information and referral to tobacco quit line * BREATHE Free group will attend 12 group meetings held on the university campus * All participants will answer interview questions related to tobacco use, character strengths and resilience * Expired Carbon Monoxide (CO) will be assessed in all participants.

Primary Outcome

Active participation in weekly session as reflected by number of weekly accomplishments

Interventions

  • BEHAVIORAL BREATHE Free Curriculum

Study Locations (1)

Georgia

  • Augusta University - Augusta

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-03-01
Est. Completion 2026-12-25
Phase NA
Augusta University

106 total trials

What NCT06862050 shows while recruiting

NCT06862050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 142-participant average among 9 other E-Cig Use trials with a reported enrollment target (37% lower).

The record links to 3 conditions, with E-Cig Use appearing as the primary indexed condition, and to 1 intervention - of which BREATHE Free Curriculum is the first listed.

NCT06862050 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT06862050 about?

NCT06862050 is a clinical study titled "BREATHE Free: a Pilot Feasibility Trial". The overall purpose of this pilot study is to assess the feasibility and acceptability of an in-person faith-based intervention to help people stop tobacco use. The study will address use of different types of tobacco products, such as smoking combustible cigarettes, cigarillos and little filtered c...

What is the current status of trial NCT06862050?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-03-01. Estimated completion is 2026-12-25.

What conditions does trial NCT06862050 study?

This clinical trial studies the following conditions: E-Cig Use, Smoking Cessation; Tobacco Dependence, Nicotine Dependence, Other Tobacco Product.

What interventions are being tested in trial NCT06862050?

The interventions under investigation include: BREATHE Free Curriculum (BEHAVIORAL).

Who is sponsoring clinical trial NCT06862050?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06862050 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for E-Cig Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06862050's enrollment target sits among peer trials

90 6th of 9 higher than 4 of 9 other E-Cig Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other E-Cig Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06862050, the US trial registry maintained by the National Library of Medicine. NCT06862050 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.